BEAM (STOCKS)
Beam Therapeutics Inc. Common Stock
$30.265400
+2.835400 (+10.34%)
Prev close: $27.430000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- John Evans
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,069.95M
- Employees
- 510
- P/E (TTM)
- -29.71
- P/B (TTM)
- 2.25
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
11
Strong Buy
11
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.10 | $-1.01 | +0.9085 | +89.82% |
|
Sep 2025 (Q3)
|
$-1.10 | $-1.06 | -0.0395 | -3.72% |
|
Jun 2025 (Q2)
|
$-1.00 | $-1.13 | +0.1319 | +11.65% |
|
Mar 2025 (Q1)
|
$-1.24 | $-1.23 | -0.0094 | -0.76% |
Financial Statements
| Revenues | $3.15B |
| Benefits Costs and Expenses | $2.67B |
| Cost Of Revenue | $1.07B |
| Cost Of Revenue, Goods | $1.07B |
| Costs And Expenses | $2.67B |
| Gross Profit | $1.48B |
| Operating Expenses | $862.30M |
| Selling, General, and Administrative Expenses | $392.20M |
| Other Operating Expenses | $470.10M |
| Operating Income/Loss | $617.10M |
| Income/Loss Before Equity Method Investments | $477.40M |
| Income/Loss From Continuing Operations After Tax | $365.50M |
| Income/Loss From Continuing Operations Before Tax | $477.40M |
| Income/Loss From Discontinued Operations Net Of Tax | -$3.00M |
| Income/Loss From Equity Method Investments | -$6.40M |
| Income Tax Expense/Benefit | $111.90M |
| Income Tax Expense/Benefit, Deferred | $47.20M |
| Interest Expense, Operating | $91.60M |
| Net Income/Loss | $362.50M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $362.50M |
| Net Income/Loss Available To Common Stockholders, Basic | $362.50M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $2.24 |
| Diluted Earnings Per Share | $2.22 |
| Basic Average Shares | 162,100,000 |
| Diluted Average Shares | 163,400,000 |
| Common Stock Dividends | $0.90 |
| Assets | $8.58B |
| Current Assets | $2.89B |
| Inventory | $1.84B |
| Other Current Assets | $1.05B |
| Noncurrent Assets | $5.69B |
| Fixed Assets | $815.70M |
| Intangible Assets | $2.22B |
| Other Non-current Assets | $2.65B |
| Liabilities | $3.51B |
| Current Liabilities | $706.60M |
| Accounts Payable | $199.80M |
| Wages | $64.70M |
| Other Current Liabilities | $442.10M |
| Noncurrent Liabilities | $2.80B |
| Long-term Debt | $2.02B |
| Other Non-current Liabilities | $779.50M |
| Equity | $5.07B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $5.07B |
| Liabilities And Equity | $8.58B |
| Net Cash Flow From Operating Activities | $423.80M |
| Net Cash Flow From Operating Activities, Continuing | $423.80M |
| Net Cash Flow From Investing Activities | -$42.30M |
| Net Cash Flow From Investing Activities, Continuing | -$42.30M |
| Net Cash Flow From Financing Activities | -$468.80M |
| Net Cash Flow From Financing Activities, Continuing | -$468.80M |
| Exchange Gains/Losses | -$1.20M |
| Net Cash Flow | -$88.50M |
| Net Cash Flow, Continuing | -$87.30M |
| Comprehensive Income/Loss | $401.70M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $401.70M |
| Other Comprehensive Income/Loss | $39.20M |